* Janssen announces discontinuation of Fulranumab phase 3 development program in Osteoarthritis pain
The post BRIEF-Janssen Pharmaceuticals terminates licensing agreement with Amgen for Fulranumab appeared first on NASDAQ.
Forex – financial instrument.Forex news
* Janssen announces discontinuation of Fulranumab phase 3 development program in Osteoarthritis pain
The post BRIEF-Janssen Pharmaceuticals terminates licensing agreement with Amgen for Fulranumab appeared first on NASDAQ.